discontinuing glp-1 Discontinuation and Reinitiation of Receptor Agonists Among US Adults with Overweight or Obesity ISPOR 2025: Exploring reasons for

Paul has been filling GLP-1 prescriptions since some of the early commercial variants received FDA approval this decade

I've not used this long enough to see a dramatic difference but I do notice a boost in hydration and radiance

Deconstruction of a neural circuit for hunger

This process may involve selecting suitable excipients, dosage forms, and delivery routes

When cagrilintide dosage with retatrutide questions arise: Appropriate Responses: Acknowledge that these are investigational compounds without approval for fitness applications Emphasize that no combination protocols exist in published research Redirect focus to evidence-based nutrition and training approaches that complement any medical interventions Suggest clients consult qualified medical professionals for peptide therapy decisions Provide education about realistic expectations and potential side effects Training Considerations: Clients using potent appetite suppressants like cagrilintide or retatrutide may experience: Reduced energy availability requiring modified training intensity Increased fatigue necessitating longer recovery periods Potential muscle loss if protein intake becomes inadequate Hydration challenges from GI side effects Programming should account for these factors, with emphasis on adequate nutrition, progressive overload appropriate to energy status, and careful monitoring of performance metrics

PMID: 30885166 6 Molecular investigation in Chinese patients with primary carnitine deficiency